Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
NCT ID: NCT04686305
Last Updated: 2025-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
244 participants
INTERVENTIONAL
2021-03-09
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The evaluation of T-DXd combination treatment with immunotherapy continues in Part 3, Part 4, and Part 5. In Part 3, T-DXd is assessed in combination with volrustomig, with carboplatin (Arm 3B) or without carboplatin (Arm 3A). Part 4 examines T-DXd with rilvegostomig, either with carboplatin (Arm 4B) or without carboplatin (Arm 4A). In Part 5, T-DXd is evaluated with volrustomig, given with or without a priming dose followed by a fixed dose in Arm 5A. There is also an optional Arm 5B at the Sponsor's discretion. These parts focus on further dose optimization for first-line HER2-overexpressing NSCLC.
For Part 3, patients will be randomized to Arms 3A and 3B, beginning with the cohorts receiving the volrustomig starting dose (SD). A total of 6 DLT-evaluable patients will be enrolled to the SD cohorts in each arm. If the combination of T-DXd with volrustomig at the starting dose is deemed safe, a dose escalation (E1) cohort will be opened for 6 DLT-evaluable patients. Once all open dose confirmation cohorts have 6 DLT-evaluable patients, the SRC will convene to select the volrustomig RP2D to be used in the dose-expansion (DE) cohorts of each arm (n=34). Part 3 is now permanently closed to recruitment; no further patients will be enrolled.
In Part 4, once a total of 6 DLT-evaluable patients/arm have been enrolled into Arm 4A and Arm 4B safety-run in (SR) cohorts and deemed safe, an additional 34 patients per arm will be enrolled in Arms 4A and 4B in dose expansion cohorts.
Part 5 involves additional dosing regimens of T-DXd in combination with volrustomig. The objective of Part 5 is to evaluate the safety and efficacy of priming and flat dosing regimens in 2 different cohorts of up to 30 patients per arm.
The target population of interest (for Part 3, 4 and 5) are patients with advanced or metastatic non-small cell lung cancer measurable disease by RECIST 1.1 criteria, HER2 overexpression, ECOG PS of 0 to 1, patients who are treatment naïve for recurrent, unresectable or metastatic disease. Patients with tumors that harbor a known genomic alteration or driver for which approved therapies are available are excluded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1A: T-DXd, Durvalumab and Cisplatin
T-DXd, Durvalumab and Cisplatin
T-DXd
T-DXd: administered as an IV infusion
Durvalumab
Durvalumab: administered as an IV infusion
Cisplatin
Cisplatin: administered as an IV infusion
Arm 1B: T-DXd, Durvalumab and Carboplatin
T-DXd, Durvalumab and Carboplatin
T-DXd
T-DXd: administered as an IV infusion
Durvalumab
Durvalumab: administered as an IV infusion
Carboplatin
Carboplatin: administered as an IV infusion
Arm 1C: T-DXd, Durvalumab and Pemetrexed
T-DXd, Durvalumab and Pemetrexed (Arm not initiated)
T-DXd
T-DXd: administered as an IV infusion
Durvalumab
Durvalumab: administered as an IV infusion
Pemetrexed
Pemetrexed: administered as an IV infusion (drug not used)
Arm 1D: T-DXd
T-DXd
T-DXd
T-DXd: administered as an IV infusion
Arm 3A: T-DXd and Volrustomig
Drug: T-DXd and Volrustomig T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Volrustomig Volrustomig: administered as an IV infusion Other Name: Volrustomig
T-DXd
T-DXd: administered as an IV infusion
Volrustomig
Volrustomig: administered as an IV infusion
Arm 3B: T-DXd, Volrustomig and Carboplatin
Drug: T-DXd, Volrustomig and Carboplatin T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Volrustomig Volrustomig: administered as an IV infusion Other Name: Volrustomig Drug: Carboplatin Carboplatin: administered as an IV infusion
T-DXd
T-DXd: administered as an IV infusion
Carboplatin
Carboplatin: administered as an IV infusion
Volrustomig
Volrustomig: administered as an IV infusion
Arm 4A: T-DXd and Rilvegostomig
T-DXd and Rilvegostomig Drug: T-DXd, Rilvegostomig T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Rilvegostomig Rilvegostomig: administered as an IV infusion Other Name: Rilvegostomig, AZD2936
T-DXd
T-DXd: administered as an IV infusion
Rilvegostomig
Rilvegostomig: administered as an IV infusion
Arm 4B T-DXd and Rilvegostomig with Carboplatin
Drug: T-DXd, Rilvegostomig and Carboplatin T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Rilvegostomig Rilvegostomig: administered as an IV infusion Other Name: Rilvegostomig, AZD2936 Drug: Carboplatin Carboplatin: administered as an IV infusion
T-DXd
T-DXd: administered as an IV infusion
Carboplatin
Carboplatin: administered as an IV infusion
Rilvegostomig
Rilvegostomig: administered as an IV infusion
Arm 5A: T-DXd and Volrustomig
Drug: T-DXd and volrustomig T-DXd: administered as an IV infusion Other Name: DS-8201a, trastuzumab deruxtecan Biological/Vaccine: Volrustomig Volrustomig: administered as an IV infusion (priming dose in first cycle, fixed dose in subsequent cycles) Other Name: volrustomig
T-DXd
T-DXd: administered as an IV infusion
Volrustomig
Volrustomig: administered as an IV infusion
Arm 5B: T-DXd and Volrustomig
Drug: T-DXd and volrustomig T-DXd: administered as an IV infusion Other Name: DS-8201a, trastuzumab deruxtecan Biological/Vaccine: Volrustomig Volrustomig: administered as an IV infusion (fixed dose from first cycle onward) Other Name: volrustomig
T-DXd
T-DXd: administered as an IV infusion
Volrustomig
Volrustomig: administered as an IV infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
T-DXd
T-DXd: administered as an IV infusion
Durvalumab
Durvalumab: administered as an IV infusion
Cisplatin
Cisplatin: administered as an IV infusion
Carboplatin
Carboplatin: administered as an IV infusion
Pemetrexed
Pemetrexed: administered as an IV infusion (drug not used)
Volrustomig
Volrustomig: administered as an IV infusion
Rilvegostomig
Rilvegostomig: administered as an IV infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Part 1: Progression after 1 or 2 lines of systemic therapy for recurrent or metastatic setting.
* Part 3, Part 4 and Part 5: Patients must have tumors that do not harbor known genomic alterations or actionable driver kinases, for which approved therapies are available are allowed.
* Part 3, Part 4 and Part 5: Patient must be treatment-naïve for advanced or metastatic NSCLC. Patients who have received prior adjuvant, or neoadjuvant chemotherapy, or definitive chemoradiation for advanced disease are eligible, provided that progression has occurred \> 6 months from end of last therapy
* HER2overexpression status as determined by central review of tumor tissue
* WHO / ECOG performance status of 0 or 1
* Measurable target disease assessed by the investigator using RECIST 1.1
* Has protocol defined adequate organ and bone marrow function
* Part 3, Part 4 and Part 5: Minimum body weight of 35 kg.
Exclusion Criteria
* Has a history of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
* Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder and prior pneumonectomy
* Active primary immunodeficiency known HIV infection, or active chronic and resolved hepatitis B (positive hepatitis B virus surface antigen \[HBsAg+ve\] or hepatitis B virus core antibody (anti-HBc +ve) regardless of HBV DNA level)) or hepatitis C infection. Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA. Patients should be tested for HIV prior to treatment assignment if required by local regulations or IRB/EC
* Active infection including tuberculosis and uncontrolled infection requiring IV antibiotics, antivirals, or antifungals
* Spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms
* Medical history of myocardial infarction within 6 months before treatment assignment, symptomatic CHF (New York Heart Association Class II to IV), clinically important cardiac arrhythmias, or a recent (\< 6 months) cardiovascular event including stroke
* For Part 3, Part 4 and Part 5: Cardiomyopathy of any etiology, symptomatic CHF (as defined by New York Heart Association Class \> II), unstable angina pectoris, history of MI within the past 12 months, or cardiac arrhythmia are to be excluded. Patients with troponin levels above ULN at screening (as defined by the manufacturer), and without any myocardial related symptoms, should have a cardiologic consultation before treatment assignment to rule out acute cardiopulmonary events.
* Ascites or pericardial effusion that requires drainage, peritoneal shunt, Pleuroperitoneal shunt or CART (Concentrated Ascites Reinfusion Therapy)
* For Part 3, Part 4 and Part 5: Active non-infectious skin disease (including any grade rash, urticarial, dermatitis, ulceration, or psoriasis) requiring systemic treatment, active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment.
* Unresolved toxicities not yet resolved to Grade ≤ 1 or baseline from previous anticancer therapy OR prior discontinuation of any planned study therapy due to toxicity.
* must not have any medical contraindication to platinum-based chemotherapy.
* Part 3, Part 4 and Part 5 patients must not have had prior exposure to anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-TIGIT or any other experimental immunotherapy in any setting.
* For Part 3, Part 4 and Part 5: History of substance abuse or any other medical or psychological conditions that may, in the opinion of the Investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results
* For Part 3, Part 4 and Part 5: History of thromboembolic events within 3 months before the first dose of IP (limited to pulmonary embolism, deep vein thrombosis, or cerebral venous sinus thrombosis).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daiichi Sankyo
INDUSTRY
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Duarte, California, United States
Research Site
Newport Beach, California, United States
Research Site
Orange, California, United States
Research Site
Santa Rosa, California, United States
Research Site
Westwood, Kansas, United States
Research Site
Baltimore, Maryland, United States
Research Site
Detroit, Michigan, United States
Research Site
Buffalo, New York, United States
Research Site
New York, New York, United States
Research Site
The Bronx, New York, United States
Research Site
Houston, Texas, United States
Research Site
Fairfax, Virginia, United States
Research Site
Tacoma, Washington, United States
Research Site
Adelaide, , Australia
Research Site
Heidelberg, , Australia
Research Site
Nedlands, , Australia
Research Site
Edegem, , Belgium
Research Site
Barretos, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
São Paulo, , Brazil
Research Site
Winnipeg, Manitoba, Canada
Research Site
London, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Fuzhou, , China
Research Site
Bordeaux, , France
Research Site
Dijon, , France
Research Site
Pierre-Bénite, , France
Research Site
Saint-Herblain, , France
Research Site
Villejuif, , France
Research Site
Kfar Saba, , Israel
Research Site
Tel Litwinsky, , Israel
Research Site
Milan, , Italy
Research Site
Milan, , Italy
Research Site
Monza, , Italy
Research Site
Napoli, , Italy
Research Site
Padua, , Italy
Research Site
George Town, , Malaysia
Research Site
Kuala Lumpur, , Malaysia
Research Site
Kuala Selangor, , Malaysia
Research Site
Kuching, , Malaysia
Research Site
Amsterdam, , Netherlands
Research Site
Bacolod, , Philippines
Research Site
Cebu City, , Philippines
Research Site
City of Taguig, , Philippines
Research Site
Davao City, , Philippines
Research Site
Manila, , Philippines
Research Site
Manila, , Philippines
Research Site
Quezon City, , Philippines
Research Site
Quezon City, , Philippines
Research Site
San Juan City, , Philippines
Research Site
Gdansk, , Poland
Research Site
Krakow, , Poland
Research Site
Olsztyn, , Poland
Research Site
Tomaszów Mazowiecki, , Poland
Research Site
Warsaw, , Poland
Research Site
Singapore, , Singapore
Research Site
Singapore, , Singapore
Research Site
Singapore, , Singapore
Research Site
Cheongju-si, , South Korea
Research Site
Goyang-si, , South Korea
Research Site
Jinju, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Badalona, , Spain
Research Site
Madrid, , Spain
Research Site
Seville, , Spain
Research Site
Valencia, , Spain
Research Site
Kaohsiung City, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Tainan, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taoyuan District, , Taiwan
Research Site
Bangkok, , Thailand
Research Site
Bangkok, , Thailand
Research Site
Hat Yai, , Thailand
Research Site
Khon Kaen, , Thailand
Research Site
Muang, , Thailand
Research Site
Muang, , Thailand
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Bornova-Izmir, , Turkey (Türkiye)
Research Site
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
AstraZeneca Clinical Study Information Center
Role: CONTACT
Phone: 1-877-240-9479
Email: [email protected]
AstraZeneca Lung Cancer Study Locator Service
Role: CONTACT
Phone: 1-884-432-3892
Email: [email protected]
Related Links
Access external resources that provide additional context or updates about the study.
Lung Cancer Study Locator details (for US)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-504949-31-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
2020-003260-31
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
D967YC00001
Identifier Type: -
Identifier Source: org_study_id